OncoMatch/Clinical Trials/NCT07100600
Trastuzumab Rezetecan Combined With Radiotherapy Versus Trastuzumab Rezetecan in the Treatment of HER2-positive Advanced Breast Cancer With Brain Metastases
Is NCT07100600 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Trastuzumab Rezetecan for her2-positive advanced breast cancer.
Treatment: Trastuzumab Rezetecan — A total of 224 subjects of HER2-positive advanced breast cancer with brain metastases are planned to be enrolled. Eligible subjects will be randomly assigned in a 1:1 ratio to the group receiving Trastuzumab Rezetecan combined with radiotherapy or the group receiving Trastuzumab Rezetecan monotherapy until disease progression, intolerable toxicity, withdrawal of informed consent, or the study determines that treatment must be terminated (whichever occurs first).
Check if I qualifyExtracted eligibility criteria
Cancer type
Breast Carcinoma
Biomarker criteria
Required: HER2 (ERBB2) overexpression
Disease stage
Metastatic disease required
Prior therapy
Cannot have received: antibody-drug conjugate (trastuzumab deruxtecan, DS-8201a)
Previous treatment with trastuzumab deruxtecan (DS-8201a) or any other antibody drug conjugate (ADC) which consists of an exatecan derivative that is a topoisomerase 1 inhibitor
Lab requirements
Blood counts
adequate function of major organs
Kidney function
adequate function of major organs
Liver function
adequate function of major organs
Cardiac function
Suffering from heart disease that is not well controlled or having clinical symptoms [excluded]
Adequate function of major organs; Suffering from heart disease that is not well controlled or having clinical symptoms [excluded]
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify